Prothena Corp. (PRTA) Says PRX003 Phase 1 as Novel Anti-MCAM Antibody Met Primary Objective
Tweet Send to a Friend
Prothena Corporation plc (Nasdaq: PRTA) announced new clinical results from a Phase 1 double blind, placebo controlled, single ascending dose ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
